Summary: The significance of MAPS’ first Phase 3 trial of MDMA-assisted therapy for PTSD is examined by Fast Company, including the fact that its results “create a pathway for the Food and Drug Administration (FDA) to approve MDMA for therapeutic use.”
Fast Company also shares the perspective of Amy Emerson, CEO of MAPS Public Benefit Corporation (MAPS PBC), who “envisions a therapeutic setting that not only treats mental illness, but provides follow-up care that addresses social hurdles like ensuring stable housing and financial management.”
Originally appearing here.
